Fat loss
Retatrutide
- 5mg*10vials USD 45.00
- 10mg*10vials USD 85.00
Reference price. The concierge confirms the amount before payment.
4.2 / 5 · 3675 reviewsAfter the order is submitted, quote the order number when you write to the concierge.
Features
Triple receptor agonist, offering the most potent fat-loss effect (24% weight reduction in clinical settings)
Overview
Retatrutide is an investigational triple-receptor agonist peptide (targeting GLP-1, GIP, and glucagon receptors) currently under development for the treatment of obesity and type 2 diabetes. Phase II clinical trials have demonstrated significant weight loss, with patients in the high-dose group achieving a weight reduction of up to 24% over 48 weeks. This educational program outlines a once-weekly subcutaneous administration regimen, incorporating a gradual dose-escalation approach to minimize gastrointestinal side effects.
Precautions
Reconstitution: Add 1.0 mL of bacteriostatic water → ~ 5.0 mg/mL concentration
Typical weekly dosage range: 2–8 mg once weekly (gradually increased over 8–12 weeks)
Easy measurement: At 5.0 mg/mL, 1 unit = 0.01 mL ≈ 50 mcg (using a U-100 insulin syringe)
How to use
1. Draw 1.0 mL of bacteriostatic water using a sterile syringe.
2. Inject slowly along the inner wall of the vial; avoid creating foam.
3. Gently swirl or roll the vial until the contents are dissolved (do not shake).
4. Label with the date and store refrigerated at 2–8°C, protected from light.
5. Use within 4 weeks of reconstitution.
Storage
Lyophilized: Store at -20°C or lower; stable for up to 24 months.
After reconstitution: Store at 2–8°C; use within 4 weeks.
Allow the vial to reach room temperature before opening to minimize condensation.
Reviews
4.2 / 5
3675 reviews
Showing the latest 100 reviews.
-
★★★★★
VX9•••••••7243
France
2026-10-25 03:55
The listing photo matched the parcel. The storage note was easy to follow. The support note helped.
-
★★★★★
VX6•••••••78DB
Canada
2026-10-25 00:02
The outer wrap was scuffed. The batch note was readable. The rest was straightforward.
-
★★★★★
VXC•••••••3034
United Kingdom
2026-10-24 20:09
The shipment was handled carefully. The order form and the parcel agreed. The whole order was tidy.
-
★★★★★
VX1•••••••B8B4
United States
2026-10-24 16:17
The box was plain and a little worn. The seal was intact. Support was accurate once they replied.
-
★★★★★
VXF•••••••625C
Germany
2026-10-24 12:24
The box was plain and a little worn. The vial was undamaged. The product side was correct.
-
★★★★★
VX0•••••••D8BB
Netherlands
2026-10-24 08:31
The paperwork was easy to read. The cap was tight. A reliable delivery.
-
★★★★★
VXE•••••••7C0B
Singapore
2026-10-24 04:39
The handoff at the depot was slow. The seal was intact. No problem with the contents.
-
★★★★★
VX0•••••••AE12
Australia
2026-10-24 00:46
The parcel was held at the depot for one day. The contents were complete. Support was accurate once they replied.
-
★★★★★
VX7•••••••8AD1
Korea
2026-10-23 20:53
The inner pack was tidy. Nothing was missing. I had no follow-up questions.
-
★★★★★
VX0•••••••DD92
United Kingdom
2026-10-23 17:00
Tracking updated a day late. The label matched the listing. The rest was straightforward.
Buyer review
Enter the order number and the phone number from checkout. Both must match an order that includes this product.
Also listed
Fat loss
Cagrilintide
Cagrilintide is a long-acting, acylated amylin analogue—a pancreatic hormone—designed for once-weekly subcutaneous injection. It activates central amylin receptors, promoting satiety, slowing gastric emptying, and reducing food intake. In Phase 2 and Phase 3 clinical trials, cagrilintide induced dose-dependent weight loss, with side effects primarily being gastrointestinal in nature.
Reference priceUSD 113.00
Fat loss
CJC-1295+IPA(CP10)
This formulation combines CJC-1295 (without DAC)—a modified growth hormone-releasing hormone (GHRH) analog—with Ipamorelin, a selective growth hormone secretagogue (GHS). CJC-1295 (without DAC) produces a sustained, dose-dependent increase in GH and IGF-1 levels, while Ipamorelin selectively stimulates GH release without increasing ACTH or cortisol.
Reference priceUSD 116.00
Fat loss
Tirzepatide
Tirzepatide is a dual incretin receptor agonist composed of 39 amino acids. It activates both GLP-1 and GIP receptors, thereby enhancing glucose-dependent insulin secretion, suppressing glucagon, delaying gastric emptying, and reducing appetite. With a half-life of approximately 5 days, it is convenient to administer via a once-weekly subcutaneous injection. Clinical trials have demonstrated that tirzepatide offers superior efficacy in terms of glycemic control and weight loss compared to selective GLP-1 receptor agonists.
Reference priceUSD 40.00
Fat loss
Tesamorelin
Tesamorelin is a synthetic 44-amino acid peptide analog that resembles growth hormone-releasing hormone (GHRH). It stimulates the release of endogenous growth hormone and increases IGF-1 levels, thereby promoting lipolysis and providing metabolic benefits. Tesamorelin has been approved by the FDA for the reduction of visceral adipose tissue in individuals with HIV-associated lipodystrophy.
Reference priceUSD 41.00